metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus dacarbazine
	nivolumab alone vs. dacarbazine	1	-2234 [-3124; -1345] /10000 50/210 vs. 96/208	-2694 [-3571; -1816] /10000 108/210 vs. 163/208	-